{"DataElement":{"publicId":"7642199","version":"1","preferredName":"Melanoma Mitotic Activity Text","preferredDefinition":"A textual description of the dividing (proliferating) activity of atypical, neoplastic melanocytes tissue cells.","longName":"7642298v1.0:6784451v1.0","context":"OCCPR","contextVersion":"1","DataElementConcept":{"publicId":"7642298","version":"1","preferredName":"Melanoma Mitotic Activity","preferredDefinition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain._Having to do with the presence of dividing (proliferating) cells. Cancerous tissue generally has more mitotic activity than normal tissues.","longName":"3108463v1.0:7222888v1.0","context":"OCCPR","contextVersion":"1","ObjectClass":{"publicId":"3108463","version":"1","preferredName":"Melanoma","preferredDefinition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes that contain melanin.  Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma.  Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi.  Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system.  Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain. -- 2004","longName":"C3224","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melanoma","conceptCode":"C3224","definition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"888ED2DC-38AD-7A5E-E040-BB89AD4317F2","latestVersionIndicator":"Yes","beginDate":"2010-06-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-08","modifiedBy":"ONEDATA","dateModified":"2010-06-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7222888","version":"1","preferredName":"Mitotic Activity","preferredDefinition":"Having to do with the presence of dividing (proliferating) cells. Cancerous tissue generally has more mitotic activity than normal tissues.","longName":"C35959","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitotic Activity","conceptCode":"C35959","definition":"Having to do with the presence of dividing (proliferating) cells. Cancerous tissue generally has more mitotic activity than normal tissues.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A1D98C4A-55A9-543B-E053-F662850AE7A6","latestVersionIndicator":"Yes","beginDate":"2020-03-27","endDate":null,"createdBy":"TSESU","dateCreated":"2020-03-27","modifiedBy":"ONEDATA","dateModified":"2020-03-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0E47C3A-9509-556C-E053-4EBD850AA6E5","latestVersionIndicator":"Yes","beginDate":"2021-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-04-26","modifiedBy":"SOKKERL","dateModified":"2023-09-08","changeDescription":"7/28/21 jk upd OC to match other CM DEC format.  4/26/21 jk created for Phase 3 CM Baseline CRF.","administrativeNotes":"9/8/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6784451","version":"1","preferredName":"255 Character Text","preferredDefinition":"The words of something written.","longName":"6784451v1.0","context":"OCCPR","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"255","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234203","version":"1","preferredName":"Text","preferredDefinition":"Text; the words of something written.","longName":"C25704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F89B-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8BA00B33-81DA-0AB8-E053-F662850A521F","latestVersionIndicator":"Yes","beginDate":"2019-06-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-18","modifiedBy":"KNABLEJ","dateModified":"2020-06-23","changeDescription":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  6-18-19 tt created for CPTAC Medical History CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6601273","version":"1","longName":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","context":"OCCPR","ClassificationSchemeItems":[{"publicId":"10000348","version":"1","longName":"Melanoma","context":"OCCPR"},{"publicId":"7634324","version":"1","longName":"CM Baseline","context":"OCCPR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"CPTAC-Phase-3-CM","type":"Alternate Question Text","description":"â‰¥1/mm2, Specify","url":null,"context":"OCCPR"},{"name":"Specify","type":"Preferred Question Text","description":"Specify","url":null,"context":"OCCPR"}],"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C0E32567-2B50-4B8C-E053-4EBD850A5A8D","latestVersionIndicator":"Yes","beginDate":"2021-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-04-26","modifiedBy":"COLBERTM","dateModified":"2022-07-11","changeDescription":"7/28/21 jk upd sys gen def.  7/27/21 jk upd DEC to match CM DEC format.  4/26/21 ls created for Phase 3 CM Baseline CRF.","administrativeNotes":"7/11/22 Updated definition for consistency per spreadsheet from JK. MR","unresolvedIssues":null,"deletedIndicator":"No"}}